Home Page

 
2025 Voxmedia Satellite Symposium Image



This event is not part of the official International Stroke Conference 2025 as planned by the American Heart Association/ American Stroke Association Committee on International Stroke Conference Program

Best Practices for Managing
Intracerebral Hemorrhage

Wednesday, February 5, 2025

Dinner and Registration:  5:30 PM - 6:00 PM PT
Symposium:                       6:00 PM - 7:30 PM PT

AC Hotel Downtown Los Angeles
Main Event Space, 7th Floor
1260 S Figueroa St.
Los Angeles, California

Chair: Joshua Goldstein, MD, PhD

Faculty: Anne Alexandrov, PhD, AGACNP-BC, ANVP-BC, CCRN,
                                       FAAN
                Christos Lazaridis MD, EDIC, BPhil
                Adnan Qureshi, MD
                Ashkan Shoamanesh, MD

Registration for this program is now closed.

 
Program Overview:

Intracerebral hemorrhage (ICH) is the most serious and least treatable form of stroke and accounts for approximately 20% of the almost 20 million new strokes that occur globally each year. Emerging evidence suggests that a number of interventions, performed early and in parallel, may improve long-term outcome. A central component of management is to provide treatment to lower blood pressure. Elevated blood pressure is common after the onset of ICH and is strongly associated with a poor outcome, and lowering towards a systolic blood pressure (SBP) of 140 mm Hg or less improves neurologic outcome. In addition to achieving goal blood pressure, smooth reduction in blood pressure without large variability is a critical element of treatment. Rapid reversal of anticoagulation in ICH patients is fundamental to improve outcome. Specific agents that reverse direct oral anticoagulants (DOACs) have demonstrated effectiveness in clinical trials and are now preferred therapies versus nonspecific agents in guidelines. Care bundles, with a focus on blood pressure management and reversal of anticoagulation, have demonstrated effectiveness and safety in improving patient outcome. Therefore, in the symposium, experts in ICH management will discuss the clinical evidence for blood pressure control and DOAC reversal and provide illustrative case studies. Results of studies focusing on bundles of care will be summarized, and faculty members will provide insights for an adoption of this strategy to improve patient outcomes.

Educational Objectives: 

  • Explain the evidence for smooth blood pressure reduction in ICH, and the various agents available.
  • Interpret clinical data for DOAC reversal agents in patients experiencing ICH
  • Summarize the evidence for bundled care in ICH


    • Target Audience: 
    This educational activity is intended for healthcare professionals managing patients experiencing a stroke.

    Accreditation & Credit Designation:

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1.0 Credits ™ through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits ™ from organizations accredited by the ACCME.

    Educational Grant:
    Voxmedia International gratefully acknowledges the educational grants from AstraZeneca Pharmaceuticals and Chiesi USA, Inc..

    Disclosure Statement:
    Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.